Antibody-Drug Conjugate– tag –
-
Daiichi Sankyo/AstraZeneca’s Datroway Receives US FDA Approval for First-Line Metastatic TNBC, EMA CHMP Gives Positive Opinion
Chemistry Today USA Overview Datroway (datopotamab deruxtecan), the TROP2-directed DXd ADC co-developed by Daiichi Sankyo and AstraZeneca, has received US FDA approval as a first-line treatment for unresectable or metastatic triple-negat... -
Antibody-Drug Conjugates Prepared with Peptide Asparaginyl Ligase Enhance Uniformity and Antitumor Activity, Promising Pharmaceutical Applications
Molecular Cancer Therapeutics (AACR Journals) USA Overview Novel antibody-drug conjugates (ADCs) prepared using peptide asparaginyl ligase (PAL) demonstrated potent antitumor activity in both in vitro and in vivo models. This innovative ... -
First-in-Class Bispecific ADC BL-B01D1 Shows Antitumor Activity in Phase Ib Trial for Relapsed Extensive-Stage Small Cell Lung Cancer
ASCO Post USA Overview The first-in-class bispecific antibody-drug conjugate (ADC), izalontamab brengitecan (iza-bren, BL-B01D1), demonstrated promising antitumor activity in a Phase Ib study for relapsed extensive-stage small cell lung ... -
Novel TROP2-Targeting ADC, hIMB1636-LDP-AE, Demonstrates Potent Antitumor Efficacy and Anti-Cancer Stem Cell Activity in Breast and Lung Cancers
Medium (@wuhanmabnus) China Overview A novel antibody-drug conjugate (ADC), hIMB1636-LDP-AE, engineered through genetic and molecular recombination technologies, has demonstrated potent antitumor efficacy in both in vitro and in vivo mod... -
WuXi Biologics Reports 18.4% H1 2026 Revenue Growth and 300 IND Application Capacity Annually, Driven by Low-Cost Strategy
Seeking Alpha China Overview WuXi Biologics announced robust financial results for H1 2026, with revenue increasing by 18.4%, primarily driven by demand for investigational drugs and multi-specific antibodies. The company has expanded it... -
AI-Designed Drug Makes Human Debut: BigHat Biosciences Begins Clinical Trial for Gastric Cancer ADC
BigHat Biosciences USA Overview BigHat Biosciences has initiated a Phase 1 clinical trial for BHB810, a novel CDH17-targeted VHH-Fc antibody-drug conjugate (ADC) designed using its AI-powered antibody design platform. Developed for gastr... -
Genentech and DualityBio Forge $1B+ Partnership to Accelerate Novel ADC Payloads, Combat Resistance
Fierce Biotech USA Overview Roche's Genentech has announced a significant collaboration with DualityBio, a deal potentially exceeding $1 billion, aimed at developing next-generation Antibody-Drug Conjugates (ADCs). This partnership will ... -
Logic-Gated Bispecific ADCs Break Toxicity Barrier, Unleash Thousands of New Cancer Targets
Drug Discovery News USA Overview A novel logic-gated platform for bispecific antibody-drug conjugates (bsADCs) shows promise in unlocking thousands of previously inaccessible cancer targets for therapeutic development. By simultaneously ... -
Advanced TME Models Unlock Novel Strategies for Enhanced ADC Therapy
Journal for ImmunoTherapy of Cancer USA Overview A recent study published in the Journal for ImmunoTherapy of Cancer modeled how the tumor immune microenvironment (TME) impedes the delivery and efficacy of antibody-drug conjugates (ADCs)... -
FDA Grants Fast Track Designation to Four Novel Cancer Therapeutics, Accelerating Development for Urgent Needs
Targeted Oncology USA Overview In August 2026, the U.S. FDA granted Fast Track designation to four novel oncology drugs, significantly accelerating their development and review processes. These include Erasca Inc.'s ERAS-0015 (pancreatic...
